Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-A2102 + disitamab vedotin
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SHR-A2102 + disitamab vedotin is an investigational combination therapy comprising two distinct antibody-drug conjugates (ADCs) targeting Nectin-4 and HER2, respectively. SHR-A2102, developed by Hengrui Pharmaceutical, consists of a humanized IgG1 monoclonal antibody against Nectin-4 conjugated to a topoisomerase I inhibitor payload via a cleavable linker. Disitamab vedotin (RC48), developed by RemeGen, is a HER2-directed ADC featuring a humanized antibody conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE). The combination is designed to provide synergistic anti-tumor activity by targeting two different cell-surface antigens frequently co-expressed in solid tumors and delivering two distinct cytotoxic payloads. It is currently being evaluated in a Phase 1b/2 clinical trial (NCT06417554) for patients with advanced solid tumors, including urothelial carcinoma, non-small cell lung cancer, and esophageal cancer.
- Other names
- SHR-A2102 + RC48
02
Targets
TOP1 (DNA Topoisomerase I)TUBB (Tubulin (alpha and beta subunits))PVRL4 (Nectin cell adhesion molecule 4)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on SHR-A2102 + disitamab vedotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-A2102 + disitamab vedotin.